Cargando…

Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy

Perhaps the greatest limitation for the continually advancing developments in cancer immunotherapy remains the immunosuppressive tumor microenvironment (TME). The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) axis is an emerging immunotherapy target, with the resulting type I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lewicky, Jordan D., Martel, Alexandrine L., Fraleigh, Nya L., Picard, Emilie, Mousavifar, Leila, Nakamura, Arnaldo, Diaz-Mitoma, Francisco, Roy, René, Le, Hoang-Thanh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782803/ https://www.ncbi.nlm.nih.gov/pubmed/36559204 http://dx.doi.org/10.3390/pharmaceutics14122710

Ejemplares similares

Synthesis & Evaluation of Novel Mannosylated Neoglycolipids for Liposomal Delivery System Applications
por: Mousavifar, Leila, et al.
Publicado: (2022)

Assessing Neutralized Nicotine Distribution Using Mice Vaccinated with the Mucosal Conjugate Nicotine Vaccine
por: Fraleigh, Nya L., et al.
Publicado: (2021)

Improving the Utility of a Dynorphin Peptide Analogue Using Mannosylated Glycoliposomes
por: Lewicky, Jordan D., et al.
Publicado: (2021)

Enhancing the Immune Response of a Nicotine Vaccine with Synthetic Small “Non-Natural” Peptides
por: Le, Hoang-Thanh, et al.
Publicado: (2020)

Assessing the immunogenicity and toxicity of the AFPL1-conjugate nicotine vaccine using heterologous and homologous vaccination routes
por: Fraleigh, Nya L., et al.
Publicado: (2019)

Strengthening peptide-based drug activity with novel glyconanoparticle
por: Lewicky, Jordan D., et al.
Publicado: (2018)

Case Reports of Situs Inversus Totalis and Dextrocardia in Sprague Dawley Rats
por: Hernández, Reynaldo Oliva, et al.
Publicado: (2019)

Repeat-Dose Toxicity Study Using the AFPL1-Conjugate Nicotine Vaccine in Male Sprague Dawley Rats
por: Oliva, Reynaldo, et al.
Publicado: (2019)

Conventional DNA-Damaging Cancer Therapies and Emerging cGAS-STING Activation: A Review and Perspectives Regarding Immunotherapeutic Potential
por: Lewicky, Jordan D., et al.
Publicado: (2023)

Evaluating the immunogenicity of an intranasal vaccine against nicotine in mice using the Adjuvant Finlay Proteoliposome (AFPL1)
por: Fraleigh, Nya L., et al.
Publicado: (2016)

Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine
por: Kripp, Melanie, et al.
Publicado: (2008)

Liposomal Cytarabine as Cancer Therapy: From Chemistry to Medicine
por: Salehi, Bahare, et al.
Publicado: (2019)

Antimicrobial susceptibility of Canadian isolates of Helicobacter pylori in Northeastern Ontario
por: Eng, Nelson F, et al.
Publicado: (2015)

Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs
por: Vazquez Fuster, Irene B., et al.
Publicado: (2020)

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

Complete Genome Sequence of Enterococcus thailandicus Strain a523 Isolated from Urban Raw Sewage
por: Ybazeta, Gustavo, et al.
Publicado: (2017)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

Design, Synthetic Strategies, and Therapeutic Applications of Heterofunctional Glycodendrimers
por: Mousavifar, Leila, et al.
Publicado: (2021)

Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm
por: Ashok Kumar, Prashanth, et al.
Publicado: (2022)

Cerebrospinal Fluid Drug Concentrations and Clinical Outcome of Patients with Neoplastic Meningitis Treated with Liposomal Cytarabine
por: Bohn, Jan-Paul, et al.
Publicado: (2019)

Nucleoside transporter-guided cytarabine-conjugated liposomes for intracellular methotrexate delivery and cooperative choriocarcinoma therapy
por: Fei, Weidong, et al.
Publicado: (2021)

Recent Development in the Design of Neoglycoliposomes Bearing Arborescent Architectures
por: Mousavifar, Leila, et al.
Publicado: (2021)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

Cytarabine delivered by CD44 and bone targeting redox-sensitive liposomes for treatment of acute myelogenous leukemia
por: Wu, Hao, et al.
Publicado: (2022)

The Exploitation of Liposomes in the Inhibition of Autophagy to Defeat Drug Resistance
por: Condello, Maria, et al.
Publicado: (2020)

Cytarabine-Induced Encephalitis
por: Lenfant, Christine, et al.
Publicado: (2021)

Comparative Study of Aryl O-, C-, and S-Mannopyranosides as Potential Adhesion Inhibitors toward Uropathogenic E. coli FimH
por: Mousavifar, Leila, et al.
Publicado: (2019)

Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study
por: van Eijkelenburg, Natasha K.A., et al.
Publicado: (2018)

Analysis of the role of intratecal liposomal cytarabine in the prophylaxis and treatment of central nervous system lymphomatosis: The Balearic Lymphoma Group experience
por: García-Recio, Marta, et al.
Publicado: (2017)

CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties
por: Mayer, Lawrence D, et al.
Publicado: (2019)

Whole brain radiotherapy combined with intrathecal liposomal cytarabine for leptomeningeal metastasis—a safety analysis and validation of the EANO-ESMO classification
por: Iglseder, Sarah, et al.
Publicado: (2022)

Exploiting innate immunity for cancer immunotherapy
por: Yi, Ming, et al.
Publicado: (2023)

Rational design of a new cytarabine-based prodrug for highly efficient oral delivery of cytarabine
por: Zhang, Jing, et al.
Publicado: (2018)

DDEL-03. LONG-TERM INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE AND LIPOSOMAL CYTARABINE: EXPERIENCE IN 75 CHILDREN AND ADOLESCENTS WITH MALIGNANT BRAIN TUMORS
por: Stepien, Natalia, et al.
Publicado: (2020)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Immunotherapies: Exploiting the Immune System for Cancer Treatment
por: Koury, Jeffrey, et al.
Publicado: (2018)

A novel cytarabine crystalline lipid prodrug: Hexadecyloxypropyl cytarabine 3′,5′-cyclic monophosphate for proliferative vitreoretinopathy
por: Kim, Jae Suk, et al.
Publicado: (2012)

Triggered Drug Release From Liposomes: Exploiting the Outer and Inner Tumor Environment
por: Franco, Marina Santiago, et al.
Publicado: (2021)

Freeze Drying of Polymer Nanoparticles and Liposomes Exploiting Different Saccharide-Based Approaches
por: Andreana, Ilaria, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uffr07d9r4pls6ibc6isj5bh30